PTK5 Inhibitors
1 drugsAbout PTK5
PTK5, or protein tyrosine kinase 5, is a protein kinase that regulates cellular processes through phosphorylation, impacting cell signaling pathways. While its precise function is still being elucidated, PTK5's role in signaling cascades makes it a potential therapeutic target.
PTK5 is targeted by one FDA-approved drug, STIVARGA, in the 'other' therapeutic area category. Currently, there is no genetic evidence data available linking PTK5 to specific diseases, highlighting an opportunity for further research.
STIVARGA (Bayer) is the only approved drug targeting PTK5, approved in 2012 and indicated for three conditions. The drug is a small molecule, representing 100% of the modality landscape for this target.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Carcinoma, Hepatocellular with only 3 trials.
Top Drugs
Bayer is the only company with an approved drug targeting PTK5.
Low competition may present an opportunity, but also indicates potential challenges in the target's viability.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PTK5, using small molecule modality.
Consider exploring alternative modalities like antibodies or PROTACs to differentiate from existing therapies.
Clinical Trials 293 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 77 | 52 | 10 | 14 | 84% |
| Phase 2 | 139 | 55 | 22 | 61 | 71% |
| Phase 3 | 66 | 46 | 8 | 12 | 85% |
| Phase 4 | 11 | 8 | 2 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
5 Phase 3 trials testing approved PTK5 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting PTK5. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2012 - 2012)
The first and only drug, STIVARGA, was approved in 2012.
The lack of recent approvals suggests a potentially saturated market or challenges in developing new PTK5-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 217 clinical trials targeting PTK5.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities